Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,562.00 JPY | -0.36% |
|
+5.56% | +15.04% |
| 08-06 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-06 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| Market Cap | 8,913B 55.96B 48.5B 45.4B 41.43B 77.96B 5,338B 79.27B 532B 209B 2,672B 210B 206B | P/E 2027 * |
44.5x | P/E 2028 * | 27.7x |
|---|---|---|---|---|---|
| Enterprise Value | 12,837B 80.6B 69.85B 65.39B 59.66B 112B 7,688B 114B 767B 300B 3,848B 303B 296B | EV / Sales 2027 * |
2.75x | EV / Sales 2028 * | 2.66x |
| Free-Float |
99.28% | Yield 2027 * |
3.66% | Yield 2028 * | 3.73% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -0.36% | ||
| 1 week | +5.56% | ||
| Current month | +0.89% | ||
| 1 month | +4.59% | ||
| 3 months | +7.62% | ||
| 6 months | -0.84% | ||
| Current year | +15.04% |
| 1 week | 5,332 |  | 5,590 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/2024 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 10/07/26 | Issuer sale | President, Japan Pharma B.U. | -1,022 | 0.0001% | ||
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36% | +5.56% | +28.01% | +25.07% | 55.96B | |
| -1.37% | +8.90% | +91.28% | +130.00% | 1,083B | |
| -0.77% | +1.91% | +49.46% | +49.44% | 626B | |
| +0.85% | +2.58% | +25.90% | +64.34% | 442B | |
| -1.65% | -0.47% | +47.32% | +37.06% | 363B | |
| -1.64% | -0.53% | +28.65% | +36.16% | 295B | |
| -1.22% | -2.84% | +5.48% | +5.22% | 248B | |
| -0.70% | +6.23% | +45.32% | +57.82% | 224B | |
| -2.99% | +1.34% | -6.94% | -51.84% | 210B | |
| +2.04% | +0.38% | +12.70% | +69.71% | 168B | |
| Average | -0.81% | +2.91% | +32.72% | +42.30% | 371.51B | |
| Weighted average by Cap. | -0.56% | +4.27% | +48.63% | +64.82% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,671B 29.33B 25.41B 23.79B 21.71B 40.85B 2,797B 41.54B 279B 109B 1,400B 110B 108B | 4,749B 29.82B 25.84B 24.19B 22.07B 41.54B 2,844B 42.24B 284B 111B 1,424B 112B 110B |
| Net income | 192B 1.21B 1.05B 978M 893M 1.68B 115B 1.71B 11.47B 4.5B 57.58B 4.53B 4.43B | 318B 1.99B 1.73B 1.62B 1.48B 2.78B 190B 2.82B 18.97B 7.43B 95.2B 7.49B 7.32B |
| Net Debt | 3,924B 24.64B 21.35B 19.99B 18.24B 34.32B 2,350B 34.9B 234B 91.82B 1,176B 92.5B 90.49B | 3,715B 23.33B 20.22B 18.93B 17.27B 32.5B 2,225B 33.04B 222B 86.95B 1,114B 87.59B 85.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/08/26 | JP¥5,562.00 | -0.36% | 3,284,000 |
| 10/08/26 | JP¥5,582.00 | +0.76% | 3,107,600 |
| 07/08/26 | JP¥5,540.00 | +2.12% | 4,116,100 |
| 06/08/26 | JP¥5,425.00 | +2.96% | 4,077,000 |
| 05/08/26 | JP¥5,269.00 | -0.32% | 3,470,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
